Glp-1 Receptor Agonists And Cancer Prevention: The Obesity-Cancer Connection And Glp-1 Receptor Agonists Protection

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

GLP-1 receptor agonists may play a role in cancer prevention by addressing obesity-related inflammation, insulin resistance, and cellular proliferation pathways, particularly in obesity-associated cancers.

# GLP-1 and Cancer Prevention: The Obesity-Cancer Connection and GLP-1 Protection

The Intertwined Epidemics: Obesity and Cancer

The global rise in obesity rates has paralleled an increase in the incidence of several types of cancer, establishing a clear and concerning link between excess adiposity and oncogenesis. Obesity is now recognized as a significant risk factor for at least 13 types of cancer, including colorectal, breast (postmenopausal), endometrial, kidney, and liver cancers [1]. The mechanisms underlying this connection are complex, involving chronic low-grade inflammation, insulin resistance, altered adipokine profiles, and increased growth factor signaling. Glucagon-like peptide-1 (GLP-1) receptor agonists, primarily known for their roles in diabetes and weight management, are emerging as potential agents in disrupting this obesity-cancer axis and offering a novel strategy for cancer prevention.

Mechanisms of GLP-1 in Cancer Prevention

GLP-1RAs exert their potential anti-cancer effects through several pathways that directly counteract the pro-oncogenic environment created by obesity:

  • Weight Loss and Adipose Tissue Modulation: The most direct mechanism is significant and sustained weight loss. By reducing overall adiposity, particularly visceral fat, GLP-1RAs decrease the production of pro-inflammatory cytokines (e.g., IL-6, TNF-alpha) and pro-angiogenic factors, and normalize adipokine levels (e.g., leptin, adiponectin). This shift from a pro-inflammatory, pro-growth environment to a more balanced state reduces the systemic drivers of cancer initiation and progression [2]. Clinical trials with GLP-1RAs have shown average weight reductions of 10-15% or more, which is comparable to bariatric surgery in terms of metabolic benefits [3].
  • Improved Insulin Sensitivity and Glucose Homeostasis: Obesity-induced insulin resistance leads to hyperinsulinemia, a known mitogenic factor that can promote cancer cell proliferation and survival. GLP-1RAs improve insulin sensitivity and glucose control, thereby reducing circulating insulin levels and mitigating this pro-growth stimulus. Lower insulin levels can directly inhibit the growth of various cancer cell lines [4].
  • Anti-inflammatory Effects: Chronic low-grade inflammation is a hallmark of obesity and a critical promoter of cancer. GLP-1RAs have demonstrated significant anti-inflammatory properties, reducing systemic inflammatory markers such such as C-reactive protein (CRP) by up to 40% in some studies [5]. This reduction in chronic inflammation can suppress tumor microenvironment signaling that supports cancer cell survival, proliferation, and metastasis.
  • Direct Cellular Effects: While less understood, some research suggests that GLP-1 receptors are expressed on certain cancer cells, and GLP-1RAs may exert direct anti-proliferative or pro-apoptotic effects. However, this area requires further investigation to differentiate between direct effects and those mediated by systemic metabolic improvements [6].
  • Clinical Context and Practical Takeaways:

    • Observational studies and meta-analyses have begun to suggest a reduced risk of certain obesity-related cancers in patients treated with GLP-1RAs. For instance, a large cohort study indicated a lower incidence of colorectal cancer in patients with type 2 diabetes on GLP-1RAs compared to other anti-diabetic medications [7]. While these findings are promising, large-scale, prospective clinical trials specifically designed to evaluate cancer prevention as a primary endpoint are needed to confirm these associations and establish causality.

    For clinicians, the potential for GLP-1RAs to contribute to cancer prevention adds another layer of benefit for patients with obesity and type 2 diabetes. When discussing treatment options, particularly for individuals with a family history of obesity-related cancers or other risk factors, the broader protective effects of GLP-1RAs should be considered. This reinforces the importance of aggressive management of obesity and metabolic dysfunction.

    Future Directions

    Future research will focus on elucidating the precise molecular pathways through which GLP-1RAs influence cancer risk, identifying specific patient populations who would benefit most from these preventive effects, and conducting randomized controlled trials to provide definitive evidence. The integration of GLP-1RAs into comprehensive cancer prevention strategies, especially for high-risk individuals, represents an exciting frontier in oncology.

    References

    [1] World Cancer Research Fund International. (2024). Diet, Nutrition, Physical Activity and Cancer: a Global Perspective. WCRF International.

    [2] Calle, E. E., et al. (2003). Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults. New England Journal of Medicine, 348(17), 1625-1638.

    [3] Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216.

    [4] Vigneri, P., et al. (2009). Diabetes and cancer. Endocrine-Related Cancer, 16(4), 1103-1123.

    [5] Hinnen, D. (2017). Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Journal of the American Association of Nurse Practitioners, 29(1), 8-18.

    [6] Marso, S. P., et al. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 375(4), 313-322.

    [7] Nauck, M. A., et al. (2021). GLP-1 receptor agonists and the risk of cancer: an updated meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 23(1), 170-179.